Comment on: A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma

por Baidoun, Firas, Merjaneh, Zahi, Abd-Elhay, Fatma Abd-Elshahed, Kamel, Mohamed Gomaa
Publicado 2021